2010
Characterization of Anti-HCV Antibodies in IL-10-Treated Patients
Eksioglu E, Bess J, Jones G, Dettloff J, Dangmeon P, Dong H, Zhu H, Firpi R, Xu Y, Nelson D, Liu C. Characterization of Anti-HCV Antibodies in IL-10-Treated Patients. Viral Immunology 2010, 23: 359-368. PMID: 20712480, PMCID: PMC2978060, DOI: 10.1089/vim.2009.0095.Peer-Reviewed Original ResearchConceptsAnti-HCV antibodiesAnti-HCV antibody titersIL-10Antibody titersTotal anti-HCV antibodyHepatitis C virus infectionC virus infectionChronic hepatitis patientsIL-10 treatmentReal-time reverse transcriptase-polymerase chain reactionReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHuh-7.5 cellsHCV-negative seraAntibody neutralization activityDisease activityHCV antibodiesViral burdenHepatitis patientsViral loadInterleukin-10Antibody responseReplicon cellsPolymerase chain reactionNeutralization antibody
2005
Impact of Humoral Immune Response on Distribution and Efficacy of Recombinant Adeno-Associated Virus-Derived Acid -Glucosidase in a Model of Glycogen Storage Disease Type II
Cresawn K, Fraites T, Wasserfall C, Atkinson M, Lewis M, Porvasnik S, Liu C, Mah C, Byrne B. Impact of Humoral Immune Response on Distribution and Efficacy of Recombinant Adeno-Associated Virus-Derived Acid -Glucosidase in a Model of Glycogen Storage Disease Type II. Human Gene Therapy 2005, 16: 68-80. PMID: 15703490, DOI: 10.1089/hum.2005.16.68.Peer-Reviewed Original ResearchConceptsGlycogen storage disease type IIImmune-tolerant miceStorage disease type IIAntibody responseContractile functionImmune responseHumoral immune responseHind limb musclesAcid alpha-glucosidaseCardiorespiratory failureType IIAntibody formationReduced glycogenGlycogen reductionLysosomal storage diseaseSoleus muscleGAA levelsMiceEnzyme levelsSkeletal muscleStorage diseaseLevel of activityMuscleRecombinant adenoAlpha-glucosidase